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Immune reconstitution inflammatory syndrome (IRIS) refers to the presence of paradoxical
clinical deterioration attributable to immune system recovery during highly active antiretro-
viral therapy (HAART). We present an immunocompetent patient with multifocal leukoen-
cephalopathy on HAART, with central nervous system (CNS) IRIS pathology of unknown
infectious etiology. CNS IRIS pathology should be suspected in patients on longstanding
HAART without immune reconstitution, presenting with unexplained leukoencephalopathy.
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CLINICAL CASE
A 48-year-old woman had three brief consecutive episodes of
dizziness and lightheadedness followed by loss of consciousness,
clonic movements of the left limbs, and gaze deviation to the
left. Despite being drowsy, she regained consciousness between
spells. A few days prior to these episodes, she was diagnosed with
a right peripheral facial paralysis and received treatment with oral
acyclovir and prednisone for 10 days. Past medical history was
remarkable for a 15-year history of acquired immune deficiency
syndrome (AIDS). At the time of such diagnosis, she presented
with recurrent pneumonias, and a CD4 count of 3 cells/mm3.
Highly active antiretroviral therapy (HAART) was immediately
initiated, she had a recovery of her immune status, remaining
stable since.
At the time of presentation to our hospital, she was on
atazanavir, ritonavir, tenofovir, and extended release didanosine.
Two weeks prior to hospital admission, the CD4 count was
513 cells/mm3 and the viral load <75 copies/ml. Pertinent find-
ings on neurological examination included a right peripheral facial
paralysis and left hand and foot adventitious movements. The
patient received 1 mg of intravenous (IV) lorazepam and 1000 mg
of IV levetiracetam with no further spells. Levetiracetam 1000 mg
every 12 h remained as scheduled medication.
Complete metabolic profile (CMP), activated partial throm-
boplastin time (aPTT), international normalized ratio (INR),
and prothrombin time (PT) were unremarkable. Complete blood
count (CBC) showed a hemoglobin of 14.3 mg/dl and a white
blood cell count (WBC) of 10.3 cells/mm3 (47% granulocytes,
43% lymphocytes, 8% monocytes, 1% eosinophils, and 1%
basophils). Rapid plasma reagin (RPR), and JC polymerase chain
reaction (PCR) serum testing were negative. Electroencephalo-
gram (EEG) showed low voltage beta activity recorded diffusely
with irregular polymorphic theta range activity. Focal slowing was
noted intermittently from a large area of the right hemisphere.
MRI of the brain with gadolinium showed diffuse T2 weighted and
fluid attenuated inversion recovery (FLAIR) non-enhancing signal
abnormalities involving the periventricular and subcortical white
matter of both cerebral hemispheres, punctate hyperintensities
on both thalami, and foci of hyperintense signal on both cere-
bellar hemispheres (Figure 1). Cerebrospinal fluid (CSF) analysis
showed one red blood cell (RBC), seven white blood cells (WBCs;
96% lymphocytes, 11% macrophages), protein of 73 mg/dl, and a
glucose of 54 (55% of serum glucose). Opening pressure was 10 cm
of CSF. Cytology and flow cytometry were negative for malignant
cells. CSF PCR analysis for JC virus, Herpes Simplex virus (HSV),
Human Herpes virus type 6 (HHV6), Epstein Bar virus (EBV),
and Varicella Zoster virus (VZV) were negative. HIV viral load on
CSF was 650 copies/ml.
Hospital course was remarkable for breakthrough partial com-
plex seizures controlled with increasing doses of levetiracetam.
She became forgetful and developed right-left disorientation, left
sided spastic hemiparesis, and progressive gait imbalance. MR
spectroscopy (MRS) of a right parietal lobe lesion was consis-
tent with diffuse neuronal loss and increased cellular turnover
(Figure 2). CT of the chest, abdomen, and pelvis was unremark-
able. Bone marrow biopsy showed no hematogenous dyscrasias,
normal smears, negative EBV PCR, and negative bacterial and
fungal cultures. Serial blood cultures failed to grow any organ-
isms. There were no signs of lymphoma affecting the eyes on
ophthalmological examination.
www.frontiersin.org February 2013 | Volume 4 | Article 12 | 1
Hornik et al. Unusual late onset CNS IRIS
FIGURE 1 | Fluid attenuated inversion recovery (FLAIR) MRI [(A),coronal; (B), axial] demonstrated showing diffuse abnormalities involving the
periventricular and subcortical white matter of both cerebral hemispheres, areas of punctate hyperintensities on both thalami, and foci of
hyperintense signal on both cerebellar hemispheres.
We recommended a brain biopsy, but the patient and fam-
ily declined, and only agreed to receive supportive therapy. Four
weeks after presentation to our hospital, the patient became
intermittently febrile and difficult to arouse. Her viral load had
increased to 684 copies/ml and the CD4 count had decreased to
410 cells/mm3. A repeat MRI showed interval progression of the
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FIGURE 2 | MR spectroscopy of a right parietal lobe abnormality (C,D)
demonstrate decrease in the N -Acetyl Aspartate peak (NAA) and
elevation of the choline peak. There is no lactate peak. While not specific,
these changes could be consistent with diffuse neuronal loss and increase
cellular turnover. (A,B) Normal parenchyma on the left parietal lobe as
control.
multifocal white matter lesions. A repeat CSF analysis showed
2RBCs, 23WBCs (95% lymphocytes), glucose of 58 mg/dl (52%
of plasma glucose), and a protein content of 110 mg/dl. Repeat
PCRs were now positive for EBV, and negative for HSV, HHV6,
JC, CMV. Antibodies against Lyme disease, Cryptococcus, and
Coccidioides were negative. Venereal Disease Research Labora-
tory (VDRL) test, cultures, smears, cytology, and flow cytome-
try were also negative. Serial blood cultures were negative. The
patient became progressively hypotensive despite hemodynamic
support with IV fluids, multiple vasopressors, and IV imipenem
suffering a fatal cardiac arrest 5 weeks after initial hospital admis-
sion. A stereotatic biopsy of a right occipital lesion was performed
4 days before patient died and its final analysis was completed
post-mortem.
PATHOLOGY
At autopsy the brain showed leptomeningeal fibrosis over the
convexities and moderate cerebral edema. Microscopic exami-
nation showed diffuse angiocentric and infiltrative inflamma-
tory infiltrates throughout the brain (Figure 3). Histological
features suggested a polyclonal appearance. Immunoperoxidase
stains showed perivascular and parenchymal lymphocytic infil-
trates primarily of CD3 positive T-cells with only some CD20
positive B-cells (Figure 4). The vast majority of the T-cells
were CD8 positive with only some focal perivascular CD4 cells
(Figure 5). There were also CD5 positive lymphocytes and some
CD 138 and B-cell lymphoma (Bcl-1) positive cells. The infil-
trates were negative for CD10, Bcl-6, and Anti-Terminal Deoxynu-
cleotidyl Transferase (TdT). Special immunoperoxidase stains for
CMV, SV40 (polyoma), HSV, EBV latent membrane protein
(LMP) were negative. The EBV in situ hybridization was equiv-
ocal/negative. Gram, Gomori–Grocott methenamine silver stain
(GMS), AFB, and Steiner stains were negative for microorganisms.
Based on the CD8+ infiltrative pattern the patient was diagnosed
with Immune Reconstitution Inflammatory Syndrome (IRIS) of
unknown source (Figure 3).
DISCUSSION
Immune reconstitution inflammatory syndrome refers to the pres-
ence of paradoxical clinical deterioration attributable to immune
system recovery during HAART. IRIS can potentially involve any
organ (Shelburne et al., 2002). Initial descriptions, considered IRIS
in two components: the immune restoration disease (IRD),and the
immune reconstitution-associated autoimmunity (Kuprica et al.,
2006; French, 2009). Certain neoplasias and cellular proliferative
diseases are also considered part of IRIS, exemplified by para-
doxical worsening of Kaposi sarcoma after initiation of HAART
(Bower et al., 2005). IRD is characterized by restoration of immu-
nity against a specific pathogen and is further divided into an
early presentation (<3 months from starting HAART) and a late
presentation (>3 months after starting HAART). Early presen-
tation IRD is best explained by an increased immune response
to either subclinical or partially treated opportunistic infections.
Late presentation IRD is characterized by an immune reaction
induced against antigens of non-viable pathogens, and has been
reported even years after onset of HAART administration (French
et al., 2004; French, 2009; Martin-Blondel et al., 2011). Patients
receiving HAART when markedly immunodeficient are more sus-
ceptible to IRIS (Phillips et al., 2005). A CD4+ T-cell count
<100 cells/ml has been identified as a major risk factor (Phillips
et al., 2005; Martin-Blondel et al., 2011). Criteria have been devel-
oped to simplify the diagnostic process (Tables 1 and 2; French
et al., 2004; Shelburne et al., 2006). An HIV RNA load reduction
and an increase onCD4+ T-cell count are cardinal features of
this syndrome. Among patients with prior defined opportunistic
infections, a meta-analysis showed a mortality rate of 4.5% and
an incidence of 16.1% for all types of IRIS (Muller et al., 2010).
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FIGURE 3 | (A,B) (Low and medium power magnification) Primarily perivascular inflammatory infiltrates with secondary lymphocytic infiltrates in the
parenchyma. (C) (High power) of white matter perivascular lymphocytic infiltrates. (D) (Low power) of perivascular and parenchymal infiltrates in the superficial
cortex and leptomeninges.
FIGURE 4 | (A) (Medium power magnification) Primarily CD3 positive T-cell perivascular inflammatory infiltrates with secondary lymphocytic infiltrates in the
brain parenchyma. (B) (Medium power) Some CD20 positive B-cells in perivascular area but very few in the surrounding brain parenchyma.
Neuroinflammatory disease driven by IRIS has been estimated
to occur in 0.9–1.5% of HIV patients started on antiretrovi-
ral agents (McCombe et al., 2009). IRIS involving the central
nervous system (CNS) has been described in association with
Mycobacterial infections (Crump et al., 1998; Foudraine et al.,
1999), Cytomegalovirus retinitis (Jacobson et al., 1997), JC virus
(Gray et al., 2005), Toxoplasma Gondii, HSV, VZV, Parvovirus B19
(Clark et al., 2004), and cryptococcal meningitis (Woods et al.,
1998; King et al., 2002). We could not find CNS IRIS related
EBV infection. Histopathologically, IRIS is characterized by a
CD8+/CD4− T-cells diffuse infiltrate, especially when produced
by viruses (Mutimer et al., 2002; Gray et al., 2003; Miller et al., 2004;
Rushing et al., 2008). A severe demyelinating leukoencephalopathy
in AIDS patients recently started on HAART has been reported
and characterized by intense astrogliosis (Langford et al., 2002;
Gray et al., 2003, 2005; Miller et al., 2004). These patients usu-
ally are less immunosuppressed than the average patients with
IRIS, having a CD4+ T-cell count above 200 cells/mm3 (Antinori
et al., 2001). Although debatable whether this represents IRIS or
a variant of HIV encephalopathy, we are unaware of any reports
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FIGURE 5 | (A,C) (Low and medium power magnification) Primarily CD8 positive T-lymphocytes in the perivascular inflammatory infiltrates and prominent
lymphocytic infiltrates in the parenchyma. (B,D) (Low and high power). Some CD4 positive T-lymphocytes in the perivascular areas but very few in brain
parenchyma infiltrates.
Table 1 | Working definition of IRIS (Shelburne et al., 2006).
a Symptoms occurring in a patient who is HIV positive currently
receiving ART
b Immunologic Response to Antiretroviral therapy, as shown by:
Decrease in HIV RNA levels from baseline
Increase in CD4 cell count from baseline
c Clinical symptoms consistent with an inflammatory process
d Clinical course not consistent with:
Expected course of a previously diagnosed opportunistic infection
Expected course of a newly diagnosed opportunistic infection
Drug toxicity
preceding the HAART era. Poor blood brain barrier penetration
of most antiretroviral medications, may explain disproportionate
CNS viral replication (Kandanearatchi et al., 2003). Patients, with
no clear infectious etiology besides HIV have been reported to have
extensive CD8+ T-cell infiltration without demyelination (Miller
et al., 2004).
Our patient presented with subacute neurological decline and
multifocal leukoencephalopathy without a clear infectious eti-
ology except for the presence of HIV RNA on CSF. HIV-gp41
immunoreactive staining was not performed on the autopsy spec-
imens. The presence of one positive PCR for EBV in the setting
of 1 negative PCR on CSF and negative studies on bone mar-
row and pathological specimens excluded acute EBV infection.
Interestingly, our patient had been on HAART for over a decade
with a stable CD4+T-cell count. Unlike usual descriptions of IRIS,
as the illness progressed, her CD4+ T-cell count declined and her
HIV serum load increased. This paradoxical progression resembles
histopathological findings of post-transplant lymphoproliferative
disease (PTLD). Although PTLD usually presents as an EBV –
B-cell disorder, it has also been described to affect T-cells (Basu
et al., 2006). Miller et al. (2004) observed similar pathological
findings, although their patients were significantly immunosup-
pressed and started on antiretrovirals 3 and 7 months prior to
their clinical presentation. Patients suffering from HIV have been
described to suffer a significant CD8 T-cell dysregulation char-
acterized by multisystem infiltration (Moulignier et al., 1997).
This syndrome called diffuse infiltrative lymphocytosis (DILS)
manifests mainly with a Sjögren’s like syndrome and multisystem
involvement. Interestingly the most common neurological man-
ifestation of this syndrome is facial paralysis (Moulignier et al.,
1997). The prevalence of DILS has significantly decreased since
the advent of HAART (Basu et al., 2006). This syndrome has not
been described to affect only the CNS.
CONCLUSION
Our patient had a multifocal leukoencephalopathy of unknown
etiology. Although autopsy was consistent with the usual patho-
logical findings of IRIS, her clinical course and immune status
were not. Our patient’s immune status remained well controlled
for decades only to deteriorate as her neurological illness pro-
gressed. This is opposite to the described clinical course of IRIS
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Table 2 | Criteria for IRIS (French et al., 2004).
Diagnosis Requires Both Major Criteria or 1 Major And 2 Minor criteria
MAJOR CRITERIA
Atypical presentation of opportunistic infections or tumors inpatients responding to ART: exaggerated and atypical inflammatory reaction; progressive
organ dysfunction or enlargement of pre-existing lesion after definitive clinical improvement with pathogen specific therapy before starting ART; or
exclusion of alternative causes (toxic effects of drug treatment, newly acquired infection or tumor or treatment failure)
Decrease in plasma HIV RNA concentration by 1 log copies per ml
MINOR CRITERIA
Increase in blood CD4 cell count after ART
Increase in an autoimmune response specific to the relevant pathogen- e.g., delayed type hypersensitivity response to mycobacterial antigens
Spontaneous resolution of disease without specific antimicrobial therapy or tumor chemotherapy with continuation of ART
were patients develop an exaggerated immune response as their
immune system recovers under the effect of antiretrovirals. Our
patient may have suffered from an immune dysregulation, perhaps
related to intrinsic CNS HIV infection. We propose that IRIS
should be diagnosed according to clinical chronological criteria
using pathology only as a supplemental diagnostic tool.
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